Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication
This article was originally published in PharmAsia News
Executive Summary
Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia